Fri, Apr 25, 2014, 2:34 AM EDT - U.S. Markets open in 6 hrs 56 mins

Recent

% | $
Quotes you view appear here for quick access.

Sunesis Pharmaceuticals, Inc. Message Board

mghmd 11 posts  |  Last Activity: Mar 16, 2014 11:15 AM Member since: Jan 22, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    A hematologist-oncologist weighs in

    by mghmd Mar 16, 2014 10:48 AM
    mghmd mghmd Mar 16, 2014 11:15 AM Flag

    the correction I intended is market cap of bio. Also, Board of Directors of CYTR includes former chairman of Sandoz, a Nobel prize winner in med., and a co-founder of Amgen.

  • Reply to

    A hematologist-oncologist weighs in

    by mghmd Mar 16, 2014 10:48 AM
    mghmd mghmd Mar 16, 2014 10:55 AM Flag

    I also like the risk/reward of CPXX and AMBI

  • Reply to

    A hematologist-oncologist weighs in

    by mghmd Mar 16, 2014 10:48 AM
    mghmd mghmd Mar 16, 2014 10:53 AM Flag

    Correction: I meant "when it has a market cap of

  • I have 40 years experience in the field, and also do biotech investing as an avocation. I bought in after the release of the of the ph 2b data when the price immediately popped 6.. While I certainly do not condone some of what happened with the company's PR , it does seem to me that CYTR was under attack by AF and many on this Board in late 2013; there has been much written on this Board that AF works for the shorts. I had an email exchange with David Hearn of CYTR on 12/16 asking him about the criticisms, I liked his response, and have continued buying. The long term price of the stock will be determined by the science. The mechanism of action of Aldox is very appealing and the available data on the drug so far is very supportive. The drug has orphan drug status, and the ph3 study is being conducted under a SPA, which is very favorable. Furthermore, the FDA is allowing unlimited use of Aldox until cancer progression; this is a huge plus since the major toxicity of anthracyline chemotherapy is dose related cardiotoxicity. . I took advantage of the recent sell off( short attack-Mr. Pearson was short when he released the SA article) to buy more CYTR. Aldox has the potential to be a blockbuster and you can buy the company when it has a market cap of 1bil with a drug only in ph1.

  • New FDA concerns about neurocognitive side effects of PCSK inhibitors make our product a lot more appealing

    Sentiment: Strong Buy

  • just off of flyonthewall

  • SGMO up 20% this morning based on success of genomic program in HIV. SGPG has exclusive partnership to utilize SGMO's gene Rx in hemophilia, etc. Looking like a wise partnership move by Shire

    Sentiment: Buy

  • stands at 10.9 according to Yahoo, down from 13..5. That is 10.9 days of average daily volume to cover. Do the shorts really want to take a chance that the BPH and cancer studies will have positive results? I doubt it. The pop with positive results will be huge. I see short covering as a positive going forward.

  • Reply to

    The Positive case for NYMX

    by mghmd Jan 30, 2014 11:32 AM
    mghmd mghmd Jan 30, 2014 12:18 PM Flag

    I forgot to mention the potential short squeeze with 13.5 days average volume sold short

  • Although there is skepticism toward the company management, particularly its secretive approach to providing information,ClinicalTrials.gov indicates a conclusion date for both phase 3 trials as April 2014. So it is likely we will have the verdict in 2Q2014.

    A Google search indicates that many urologists involved in the trials( who are not paid consultants for the company) have publicly praised the ease of use and efficacy of NX-1207. The drug only has to do significantly better then the saline placebo in the phase3 studies, which seems highly likely. The independent safety review board has already cleared the drug. Hence, I see a high likelihood of FDA approval. Urology colleagues tell me there is a strong need for a simple, office based procedure for BPH, which afflicts 40% of men over 50. The procedure will almost certainly be a money maker for urologists, and there is a huge reservoir of symptomatic men who are afraid of surgery but would be eager for a simple office procedure, so a rapid ramp-up is very likely. Add on the possibility of an effective Rx for low grade prostate cancer, and I think you have a compelling risk reward scenario.

    Sentiment: Strong Buy

  • The phase 2 studies on nx-1207 are favorable, and the comments of several urologists are also quite favorable. The drug is being compared to a placebo, which sets a low bar. I remain optimistic that the drug will prove quite superior to the placebo injection. The safety studies have also uniformly been favorable. I am optimistic for an easy FDA approval

    Sentiment: Buy

SNSS
5.29-0.07(-1.31%)Apr 24 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
GW Pharmaceuticals plc
NasdaqGMThu, Apr 24, 2014 4:00 PM EDT
Apple Inc.
NasdaqGSThu, Apr 24, 2014 4:00 PM EDT